-
Something wrong with this record ?
Role of Adipose Tissue in Inflammatory Bowel Disease
E. Karaskova, M. Velganova-Veghova, M. Geryk, H. Foltenova, V. Kucerova, D. Karasek
Language English Country Switzerland
Document type Journal Article, Review
Grant support
FNOL 00098892
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
33921758
DOI
10.3390/ijms22084226
Knihovny.cz E-resources
- MeSH
- Obesity, Abdominal immunology metabolism MeSH
- Adipokines metabolism MeSH
- Inflammatory Bowel Diseases immunology metabolism MeSH
- Humans MeSH
- Intra-Abdominal Fat immunology metabolism MeSH
- Adipose Tissue immunology metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Inflammatory bowel diseases (IBDs), chronic inflammatory disorders affecting the gastrointestinal tract, include Crohn's disease and ulcerative colitis. There are increasing clinical and experimental data showing that obesity, especially visceral adiposity, plays a substantial role in the pathogenesis of IBD. Obesity seems to be an important risk factor also for IBD disease severity and clinical outcomes. Visceral adipose tissue is an active multifunctional metabolic organ involved in lipid storage and immunological and endocrine activity. Bowel inflammation penetrates the surrounding adipose tissue along the mesentery. Mesenteric fat serves as a barrier to inflammation and controls immune responses to the translocation of gut bacteria. At the same time, mesenteric adipose tissue may be the principal source of cytokines and adipokines responsible for inflammatory processes associated with IBD. This review is particularly focusing on the potential role of adipokines in IBD pathogenesis and their possible use as promising therapeutic targets.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018814
- 003
- CZ-PrNML
- 005
- 20210830100359.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22084226 $2 doi
- 035 __
- $a (PubMed)33921758
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Karaskova, Eva $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 245 10
- $a Role of Adipose Tissue in Inflammatory Bowel Disease / $c E. Karaskova, M. Velganova-Veghova, M. Geryk, H. Foltenova, V. Kucerova, D. Karasek
- 520 9_
- $a Inflammatory bowel diseases (IBDs), chronic inflammatory disorders affecting the gastrointestinal tract, include Crohn's disease and ulcerative colitis. There are increasing clinical and experimental data showing that obesity, especially visceral adiposity, plays a substantial role in the pathogenesis of IBD. Obesity seems to be an important risk factor also for IBD disease severity and clinical outcomes. Visceral adipose tissue is an active multifunctional metabolic organ involved in lipid storage and immunological and endocrine activity. Bowel inflammation penetrates the surrounding adipose tissue along the mesentery. Mesenteric fat serves as a barrier to inflammation and controls immune responses to the translocation of gut bacteria. At the same time, mesenteric adipose tissue may be the principal source of cytokines and adipokines responsible for inflammatory processes associated with IBD. This review is particularly focusing on the potential role of adipokines in IBD pathogenesis and their possible use as promising therapeutic targets.
- 650 _2
- $a adipokiny $x metabolismus $7 D054392
- 650 _2
- $a tuková tkáň $x imunologie $x metabolismus $7 D000273
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiopatické střevní záněty $x imunologie $x metabolismus $7 D015212
- 650 _2
- $a nitrobřišní tuk $x imunologie $x metabolismus $7 D050152
- 650 _2
- $a abdominální obezita $x imunologie $x metabolismus $7 D056128
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Velganova-Veghova, Maria $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Geryk, Milos $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Foltenova, Hana $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Kucerova, Veronika $u Department of Clinical Biochemistry, University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Karasek, David $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 8 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33921758 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100359 $b ABA008
- 999 __
- $a ok $b bmc $g 1689793 $s 1139260
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 8 $e 20210419 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a FNOL 00098892 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20210728